| # | Title | Journal | Year | Citations |
|---|
| 1 | Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors | Investigational New Drugs | 2017 | 647 |
| 2 | Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria | Investigational New Drugs | 1992 | 559 |
| 3 | Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine | Investigational New Drugs | 2014 | 452 |
| 4 | Phase II trial of gemcitabine (2,2?-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas | Investigational New Drugs | 1994 | 424 |
| 5 | Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme | Investigational New Drugs | 2005 | 402 |
| 6 | Matrix metalloproteinase inhibitors | Investigational New Drugs | 1997 | 400 |
| 7 | 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development | Investigational New Drugs | 2000 | 331 |
| 8 | Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy | Investigational New Drugs | 2015 | 327 |
| 9 | A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma | Investigational New Drugs | 2014 | 302 |
| 10 | Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer | Investigational New Drugs | 2013 | 297 |
| 11 | A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma | Investigational New Drugs | 2011 | 285 |
| 12 | Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity | Investigational New Drugs | 1999 | 277 |
| 13 | A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction | Investigational New Drugs | 2011 | 269 |
| 14 | Role of formulation vehicles in taxane pharmacology | Investigational New Drugs | 2001 | 261 |
| 15 | A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients | Investigational New Drugs | 2006 | 259 |
| 16 | The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor | Investigational New Drugs | 2008 | 234 |
| 17 | Proteasome inhibition: a new strategy in cancer treatment | Investigational New Drugs | 2000 | 223 |
| 18 | Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer | Investigational New Drugs | 2012 | 213 |
| 19 | Ipilimumab associated hepatitis: imaging and clinicopathologic findings | Investigational New Drugs | 2013 | 211 |
| 20 | Aurora kinase inhibitors: Progress towards the clinic | Investigational New Drugs | 2012 | 201 |
| 21 | A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy | Investigational New Drugs | 2012 | 196 |
| 22 | Development of artemisinin compounds for cancer treatment | Investigational New Drugs | 2013 | 195 |
| 23 | First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies | Investigational New Drugs | 2013 | 187 |
| 24 | Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing | Investigational New Drugs | 2001 | 184 |
| 25 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer | Investigational New Drugs | 2011 | 179 |
| 26 | Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia | Investigational New Drugs | 2017 | 178 |
| 27 | A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer | Investigational New Drugs | 2015 | 170 |
| 28 | A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors | Investigational New Drugs | 2014 | 167 |
| 29 | Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors | Investigational New Drugs | 2014 | 167 |
| 30 | Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Investigational New Drugs | 2014 | 165 |
| 31 | Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer | Investigational New Drugs | 2008 | 164 |
| 32 | Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads | Investigational New Drugs | 2018 | 157 |
| 33 | A phase II study of taxol in patients with malignant melanoma | Investigational New Drugs | 1991 | 155 |
| 34 | Response rates, duration of response, and dose response effects in phase I studies of antineoplastics | Investigational New Drugs | 1991 | 154 |
| 35 | Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer | Investigational New Drugs | 2008 | 154 |
| 36 | Kidney injuries related to ipilimumab | Investigational New Drugs | 2014 | 153 |
| 37 | From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates | Investigational New Drugs | 2006 | 152 |
| 38 | Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma | Investigational New Drugs | 2018 | 150 |
| 39 | Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions | Investigational New Drugs | 2005 | 149 |
| 40 | Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience | Investigational New Drugs | 2018 | 149 |
| 41 | Oral delivery of taxanes | Investigational New Drugs | 2001 | 146 |
| 42 | Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2 | Investigational New Drugs | 2011 | 146 |
| 43 | Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel™ | Investigational New Drugs | 2005 | 144 |
| 44 | A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells | Investigational New Drugs | 2008 | 142 |
| 45 | Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma | Investigational New Drugs | 2003 | 140 |
| 46 | LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models | Investigational New Drugs | 2013 | 140 |
| 47 | Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles | Investigational New Drugs | 1992 | 139 |
| 48 | Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers | Investigational New Drugs | 2004 | 138 |
| 49 | Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study | Investigational New Drugs | 2012 | 138 |
| 50 | Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD) | Investigational New Drugs | 1993 | 137 |
